Regencell Bioscience Holdings Limited (RGC)

RGC Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cash & Equivalents	-	2.96	1.56	6.42	0.06	0.39
Short-Term Investments	-	5	10	10	-	-
Cash & Short-Term Investments	-	7.96	11.56	16.42	0.06	0.39
Cash Growth	-	-31.16%	-29.56%	27532.00%	-84.65%	59.05%
Prepaid Expenses	-	0.15	0.06	0.03	0.01	-
Total Current Assets	6.59	8.11	11.62	16.44	0.07	0.39
Property, Plant & Equipment	-	0.23	0.89	1.46	0.08	0.11
Long-Term Deferred Charges	-	-	-	-	0.17	-
Other Long-Term Assets	0.89	0.1	0.11	0.11	0.02	0.02
Total Assets	7.48	8.44	12.62	18.02	0.34	0.51
Accrued Expenses	-	0.13	0.16	0.15	0.57	0.1
Short-Term Debt	-	-	-	-	3.68	3.07
Current Portion of Leases	-	0.06	0.44	0.41	-	-
Other Current Liabilities	-	0.01	0.01	0.02	0.08	-
Total Current Liabilities	-	0.19	0.61	0.58	4.34	3.16
Long-Term Leases	-	0.03	0.03	0.36	-	-
Total Liabilities	0.76	0.22	0.63	0.94	4.34	3.16
Common Stock	6.72	0	0	0	0	0
Additional Paid-In Capital	-	29.88	29.43	28.51	0	0
Retained Earnings	-	-21.62	-17.32	-11.44	-4	-2.65
Comprehensive Income & Other	-	-0.05	-0.09	-	-	-
Total Common Equity	6.72	8.22	12.03	17.07	-4	-2.65
Minority Interest	-	-	-0.04	0.02	-	-
Shareholders' Equity	6.72	8.22	11.99	17.08	-4	-2.65
Total Liabilities & Equity	7.48	8.44	12.62	18.02	0.34	0.51
Total Debt	-	0.09	0.46	0.77	3.68	3.07
Net Cash (Debt)	-	7.88	11.1	15.65	-3.62	-2.68
Net Cash Growth	-	-29.06%	-29.05%	-	-	-
Net Cash Per Share	-	0.02	0.02	0.03	-0.01	-0.01
Filing Date Shares Outstanding	494.49	494.49	494.49	494.49	380	380
Total Common Shares Outstanding	494.49	494.49	494.49	494.49	380	380
Working Capital	6.59	7.92	11.01	15.87	-4.27	-2.78
Book Value Per Share	0.01	0.02	0.02	0.03	-0.01	-0.01
Tangible Book Value	6.72	8.22	12.03	17.07	-4	-2.65
Tangible Book Value Per Share	0.01	0.02	0.02	0.03	-0.01	-0.01
Machinery	-	0.3	0.3	0.3	-	-
Leasehold Improvements	-	0.62	0.62	0.6	0.12	0.12

Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q